Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.39 |
| ▸ | GHSR | Q92847 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377673 | 1.00 | ROCK2 (0.42) | ROCK2ACACBABCB1ABCG2GHSR | |
| SCHEMBL19377207 | 0.91 | THRB (0.39) | ROCK2ACACBGHSRALDH1A1 | |
| SCHEMBL19377059 | 0.91 | PDE4B (0.39) | ACACBABCB1ABCG2GHSRKDM4E | |
| SCHEMBL19377118 | 0.91 | ACACB (0.40) | ACACBABCB1ABCG2GHSRALDH1A1 | |
| SCHEMBL19377060 | 0.91 | PDE4B (0.39) | ACACBABCB1ABCG2GHSRKDM4E | |
| SCHEMBL19377208 | 0.91 | THRB (0.39) | ROCK2ACACBGHSRALDH1A1 | |
| SCHEMBL19377117 | 0.91 | ACACB (0.40) | ACACBABCB1ABCG2GHSRALDH1A1 | |
| SCHEMBL19377083 | 0.90 | MAPT (0.38) | ROCK2ACACBGHSRMLNR | |
| SCHEMBL19377081 | 0.90 | MAPT (0.38) | ROCK2ACACBGHSRMLNR | |
| SCHEMBL19377186 | 0.87 | ROCK2 (0.43) | ROCK2ACACBGHSRCYP3A4MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | disclosed |
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | ROCK2 4208/4885ACACB 2049/4885ABCB1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.